Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Petter Bjornstad · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Seattle Children's Hospital · NCT05008276
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 8–14 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 100
- US sites recruiting
- 2
- Study start
- September 27, 2021
- Record last updated
- March 24, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.
Being studied: Aminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Dextran 40
Conditions: Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Adolescent Obesity; Pre Diabetes; Kidney Hypoxia; Puberty
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- HbA1c ≥6.0% for untreated high-risk group
- BMI ≥ 85th %ile for high-risk group
- Normal HbA1c ≤5.6% for control group
- Type 1 diabetes (T1D) Antibody negative
Exclusion Criteria
- History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
- Metabolic disorder prohibiting safe fasting
- Iodine or penicillin allergy
- Pregnancy
- Thrombophilia
- MRI contraindications
- Hormone therapy
Recruiting US locations
Children's Hospital Colorado
Aurora, CO 80045
Site contact: Megan Kelsey, MD, MS · 720-777-0991 · Megan.Kelsey@childrenscolorado.org
Seattle Children's Hospital
Seattle, WA 98102
Site contact: Petter M Bjornstad, MD · (206) 616 3543 · pettermb@uw.edu
Study contacts (from the official record)
- Petter Bjornstad, MD · (206) 616 3543 · pettermb@uw.edu
Similar studies in Colorado
All weight loss studies in Colorado →- RecruitingHealthy volunteersPhase 1
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
University of Colorado, Denver
- Location
- Aurora, CO
- Eligibility basics
- Ages 19–37 · Women only
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Arvada, CO + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company
- Location
- Lakewood, CO + 17 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Aurora, CO + 59 other US sites
- Eligibility basics
- Ages 18+